Phase III trial of hPAM4-Cide (90Y-labelled clivatuzumab tetraxetan) in pancreatic cancer terminated early due to low efficacy- Immunomedics
Immunomedics has announced that the Company is terminating the Phase III PANCRIT-1 trial with hPAM4-Cide (yttrium-90-labeled (90Y) clivatuzumab tetraxetan) in patients with metastatic pancreatic cancer who had received at least two prior therapies, one of which must have been a gemcitabine-containing regimen. The decision to terminate the trial early is based on the recommendation from the independent Data and Safety Monitoring Board (DSMB), following a planned interim analysis of data on overall survival (OS) after more than 50% of the required 371 deaths had occurred.
The interim analysis showed that the treatment arm of 90Y-clivatuzumab tetraxetan combined with low-dose gemcitabine and best supportive care did not demonstrate a sufficient improvement in OS as compared to placebo plus low-dose gemcitabine and best supportive care.
Comment: Yttrium (90Y) clivatuzumab tetraxetan is a humanized monoclonal antibody designed for the treatment of pancreatic cancer. The antibody itself, clivatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90, a radioisotope which destroys the tumour cells.
Related news and insights
Medtronic plc announced three-month results from an on-label, prospective, multi-center study showing meaningful pain relief using DTM SCS endurance therapy, a modified, lower-energy variation of the company's Differential Target Multiplexed (DTM) Spinal Cord Stimulation (SCS) therapy for chronic overall, back or leg pain.
Pfizer Inc. announced that FDA approved Cibinqo (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of adults living with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
Pfizer Inc. announced positive top-line results from a Phase III study (B7471026) describing the safety and immunogenicity of Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in the United States 65 years of age or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.